Production of CanSino Biologics not yet affected by Tianjin Omicron infections: report
Published: Jan 10, 2022 12:34 AM
Photo: Courtesy of CanSinoBIO

Photo: Courtesy of CanSinoBIO

CanSino Biologics, Tianjin-based COVID-19 vaccine maker, said its production and operations remain unaffected by the local coronavirus flareup for the time being, media reported on Sunday after the northern Chinese municipality recorded cases of the Omicron variant. 

Currently, CanSino Biologics' operations are not yet affected by the local virus situation and the company's future moves will be contingent on the results of a citywide nucleic acid testing, online financial news outlet reported, citing an unidentified company source. 

The vaccine maker, traded in both Shanghai and Hong Kong markets, has not yet confirmed the report in stock filings. 

Tianjin has declared a citywide testing after 20 people tested positive for coronavirus, authorities revealed on Sunday according to Xinhua News Agency.

The cases were reported between Friday and Saturday in the city's Jinnan district, with the gene sequencing detecting the first two locally confirmed infections with the new variant according to the municipal center for disease control and prevention, Xinhua announced